Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients
John M Pagel, Stephen E Spurgeon, John C Byrd, Farrukh T Awan, Ian W Flinn, Mark C Lanasa, Amy J Eisenfeld, Scott C Stromatt, Ajay K Gopal, John M Pagel, Stephen E Spurgeon, John C Byrd, Farrukh T Awan, Ian W Flinn, Mark C Lanasa, Amy J Eisenfeld, Scott C Stromatt, Ajay K Gopal
Abstract
CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel humanized anti-CD37 protein therapeutic. Patients with relapsed or refractory follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), or Waldenström's macroglobulinaemia (WM) received otlertuzumab at 20 mg/kg administered intravenously once a week for up to 8 weeks followed by 4 monthly doses. Sixteen patients were treated; median age was 62·5 years (range, 41-81), and median number of prior regimens was 4 (range, 1-7). Twelve patients were refractory to prior treatment, 5 were refractory to rituximab. The mean terminal half-life was 9·5 days. Lymph node reduction of ≥50% by computerized tomography scan measurements was seen in 3 of 12 patients, including one FL patient who had a partial response. One WM patient had a minor response. The most frequent adverse events were neutropenia, fatigue, nausea, thrombocytopenia, diarrhoea, and peripheral oedema; most were grade 1/2. Otlertuzumab treatment appears to have been well tolerated by the patients in this study. Clinical activity was observed in this small heterogeneous cohort of highly refractory, heavily pretreated B-cell non-Hodgkin lymphoma patients. These data suggest that further clinical investigation in non-Hodgkin lymphoma is warranted.
Keywords: antiCD37; clinical trial; non-Hodgkin Lymphoma; otlertuzumab.
© 2014 John Wiley & Sons Ltd.
Source: PubMed